AstraZeneca (LON:AZN) Given a GBX 7,900 Price Target by JPMorgan Chase & Co. Analysts

JPMorgan Chase & Co. set a GBX 7,900 ($103.23) price target on AstraZeneca (LON:AZN) in a report published on Monday, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the subject of several other reports. Liberum Capital reaffirmed a hold rating and set a GBX 6,400 ($83.63) price objective on shares of AstraZeneca in a research report on Wednesday, August 28th. Barclays lifted their price objective on shares of AstraZeneca from GBX 7,800 ($101.92) to GBX 8,000 ($104.53) and gave the stock an overweight rating in a research report on Friday, September 6th. Deutsche Bank raised shares of AstraZeneca to a buy rating and lifted their price objective for the stock from GBX 7,200 ($94.08) to GBX 7,600 ($99.31) in a research report on Monday, September 2nd. UBS Group reaffirmed a sell rating on shares of AstraZeneca in a research report on Wednesday, August 21st. Finally, Credit Suisse Group set a GBX 7,300 ($95.39) price objective on shares of AstraZeneca and gave the stock a buy rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and an average target price of GBX 6,956.25 ($90.90).

Shares of AZN stock opened at GBX 6,904 ($90.21) on Monday. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 52 week low of GBX 5,312 ($69.41) and a 52 week high of GBX 7,583 ($99.09). The stock has a market capitalization of $90.57 billion and a PE ratio of 40.33. The firm has a 50 day moving average of GBX 7,124.24 and a two-hundred day moving average of GBX 6,384.29.

The business also recently declared a dividend, which was paid on Monday, September 9th. Investors of record on Thursday, August 8th were paid a dividend of GBX 71.90 ($0.94) per share. The ex-dividend date was Thursday, August 8th. This represents a yield of 1.07%. AstraZeneca’s dividend payout ratio is currently 1.28%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: What is the price-sales ratio?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.